With the preliminary report of 94 134 overdose deaths in the US for the 12 months ending on January 1, 2021, it is likely that 2020, in addition to being marred by COVID-19, was also the most deadly drug overdose year on record.1 This unacceptable human toll highlights the urgent need for new strategies to combat the opioid epidemic, particularly as overdoses increasingly involve stimulants and other substances. Building on clinical trials demonstrating the efficacy of medications for opioid use disorder (MOUD), prevailing approaches have emphasized the role of treatment.2 Those approaches remove barriers to treatment, such as expanding treatment coverage and increasing treatment availability with hub-and-spoke models. In these models, treatment seeking, even if influenced by need, predisposing, and enabling factors, is ultimately an individual act.2